Cargando…
Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients
We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902513/ https://www.ncbi.nlm.nih.gov/pubmed/28144792 http://dx.doi.org/10.1007/s10461-017-1683-z |
_version_ | 1783314767385985024 |
---|---|
author | Haddow, Lewis J. Laverick, Rosanna Daskalopoulou, Marina McDonnell, Jeffrey Lampe, Fiona C. Gilson, Richard Speakman, Andrew Antinori, Andrea Balestra, Pietro Bruun, Tina Gerstoft, Jan Nielsen, Lars Vassilenko, Anna Collins, Simon Rodger, Alison J. |
author_facet | Haddow, Lewis J. Laverick, Rosanna Daskalopoulou, Marina McDonnell, Jeffrey Lampe, Fiona C. Gilson, Richard Speakman, Andrew Antinori, Andrea Balestra, Pietro Bruun, Tina Gerstoft, Jan Nielsen, Lars Vassilenko, Anna Collins, Simon Rodger, Alison J. |
author_sort | Haddow, Lewis J. |
collection | PubMed |
description | We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤−1 in at least 2 out of 5 cognitive domains. Participants’ mean age was 45.8 years; 84% male; 87% white; 56% university educated; median CD4 count 550 cells/mm(3); 89% on antiretroviral therapy. 156 (35%) participants had NCI, among whom 26 (17%; 5.8% overall) reported a decline in activities of daily living. Prevalence of NCI was lower in those always able to afford basic needs (adjusted prevalence ratio [aPR] 0.71, 95% confidence interval [CI] 0.54–0.94) or with a university education (aPR 0.72, 95% CI 0.54–0.97) and higher in those with severe depressive symptoms (aPR 1.53, 95% CI 1.09–2.14) or a significant comorbid condition (aPR 1.40, 95% CI 1.03–1.90). |
format | Online Article Text |
id | pubmed-5902513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-59025132018-04-24 Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients Haddow, Lewis J. Laverick, Rosanna Daskalopoulou, Marina McDonnell, Jeffrey Lampe, Fiona C. Gilson, Richard Speakman, Andrew Antinori, Andrea Balestra, Pietro Bruun, Tina Gerstoft, Jan Nielsen, Lars Vassilenko, Anna Collins, Simon Rodger, Alison J. AIDS Behav Original Paper We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤−1 in at least 2 out of 5 cognitive domains. Participants’ mean age was 45.8 years; 84% male; 87% white; 56% university educated; median CD4 count 550 cells/mm(3); 89% on antiretroviral therapy. 156 (35%) participants had NCI, among whom 26 (17%; 5.8% overall) reported a decline in activities of daily living. Prevalence of NCI was lower in those always able to afford basic needs (adjusted prevalence ratio [aPR] 0.71, 95% confidence interval [CI] 0.54–0.94) or with a university education (aPR 0.72, 95% CI 0.54–0.97) and higher in those with severe depressive symptoms (aPR 1.53, 95% CI 1.09–2.14) or a significant comorbid condition (aPR 1.40, 95% CI 1.03–1.90). Springer US 2017-01-31 2018 /pmc/articles/PMC5902513/ /pubmed/28144792 http://dx.doi.org/10.1007/s10461-017-1683-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Haddow, Lewis J. Laverick, Rosanna Daskalopoulou, Marina McDonnell, Jeffrey Lampe, Fiona C. Gilson, Richard Speakman, Andrew Antinori, Andrea Balestra, Pietro Bruun, Tina Gerstoft, Jan Nielsen, Lars Vassilenko, Anna Collins, Simon Rodger, Alison J. Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients |
title | Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients |
title_full | Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients |
title_fullStr | Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients |
title_full_unstemmed | Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients |
title_short | Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients |
title_sort | multicenter european prevalence study of neurocognitive impairment and associated factors in hiv positive patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902513/ https://www.ncbi.nlm.nih.gov/pubmed/28144792 http://dx.doi.org/10.1007/s10461-017-1683-z |
work_keys_str_mv | AT haddowlewisj multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT laverickrosanna multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT daskalopouloumarina multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT mcdonnelljeffrey multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT lampefionac multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT gilsonrichard multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT speakmanandrew multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT antinoriandrea multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT balestrapietro multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT bruuntina multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT gerstoftjan multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT nielsenlars multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT vassilenkoanna multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT collinssimon multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT rodgeralisonj multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients AT multicentereuropeanprevalencestudyofneurocognitiveimpairmentandassociatedfactorsinhivpositivepatients |